Detailed Reanalysis of 500 Breast Cancers With Equivocal HER2 Immunohistochemistry and Borderline ERBB2 Fluorescence In Situ Hybridization Results

Online journal article in Surgical Pathology that offers 1.0 continuing education (CME) credit that can be used to fulfill CC Part II requirements.

Quantity:

Want to save more?

Log into see if you qualify for a lower rate.

Members

save $5.00 or more

Intended Audience: Pathologists, Residents, Clinical Scientists, Pathologist Assistants

Upon completion of this activity, you will be able to:

Describe the workflow for ERBB2 (HER2) testing on breast cancers with borderline (group 2, group 3, or group 4) FISH results according to updated (2018)...

Intended Audience: Pathologists, Residents, Clinical Scientists, Pathologist Assistants

Upon completion of this activity, you will be able to:

Describe the workflow for ERBB2 (HER2) testing on breast cancers with borderline (group 2, group 3, or group 4) FISH results according to updated (2018) guidelines
Discuss common reasons for result discrepancies in HER2 immunohistochemistry and ERBB2 FISH for breast cancers with FISH results in groups 2, 3, or 4
Identify practice barriers for reference laboratories in implementing the updated (2018) guidelines for ERBB2 (HER2) testing

View More View Less